Examples of using C-kit in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
There are no controlled trials in paediatric patients with c-Kit positive GIST.
The SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor GIST.
Canine mast cell tumour growth is frequently driven by an activating mutation in c-Kit.
The presence of a mutated tyrosine kinase c-kit receptor must be confirmed prior to treatment.
These enzymes can be found in some receptors onthe surface of cells, including the c-kit receptor.
The presence of a mutated tyrosine kinase c-kit receptor must be confirmed prior to treatment see also 5.1.
The study population included dogs whose tumours contained mutated or normal('wild-type') c-kit receptors.
RAF kinases are serine/ threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases.
Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor(PDGF) andstem cell factor(SCF)/c-kit;
Imatinib Mesylate is a specific tyrosine kinase(abl, c-kit, and PDGFR) inhibitor and is reported to sensitize cells to radio- or chemo-therapy.
Toceranib induces cell cycle arrest and subsequent apoptosis in tumour cell lines expressing activating mutations in the split kinase RTK, c-Kit.
The majority of paediatric patients treated for GIST lacked data confirming c-kit or PDGFR mutations which may have led to mixed clinical outcomes.
Bosutinib is also an inhibitor of Src family kinases including Src, Lyn andHck; Bosutinib minimally inhibits PDGF receptor and c-Kit.
Sorafenib inhibits the activity of targets present in the tumour cell(CRAF, BRAF,V600E BRAF, c-KIT, and FLT-3) and in the tumour vasculature CRAF, VEGFR-2, VEGFR-3, and PDGFR-ß.
In the dogs whose tumours contained mutated c-kit receptors, it took longer for the tumour to get worse when dogs received Masivet(median of 241 days) than in those receiving placebo median of 83 days.
In preclinical experiments, pazopanib dose-dependently inhibited ligand-induced auto-phosphorylation of VEGFR-2, c-Kit and PDGFR- receptors in cells.
In dogs with non- resectable mast cell tumours, Grade 2 or 3,expressing a mutated tyrosine kinase c-kit receptor, treatment with Masivet showed a significantly longer Time-to-Tumour Progression(TTP) with a median of 241 days as compared to 83 days for placebo.
Dasatinib inhibits the activity of the BCR-ABL kinase andSRC family kinases along with a number of other selected oncogenic kinases including c-KIT, ephrin(EPH) receptor kinases, and PDGFβ receptor.
Imatinib is a small molecule protein kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase(TK), as well as several receptor TKs: Kit, the receptor for stem cell factor(SCF)coded for by the c-Kit proto-oncogene, the discoidin domain receptors(DDR1 and DDR2), the colony stimulating factor receptor(CSF-1R) and the platelet-derived growth factor receptors alpha and beta PDGFR-alpha and PDGFR-beta.
Toceranib inhibited the activity of Flk- 1/KDR tyrosine kinase(vascular endothelial growth factor receptor, VEGFR2), platelet-derived growth factor receptor(PDGFR) andstem cell factor receptor(c-Kit) in both biochemical and cellular assays.